Immunic initiated with a Buy at EF Hutton

EF Hutton analyst Jason Kolbert initiated coverage of Immunic with a Buy rating and $17 price target. Immunic is a pivotal Phase 3 biotechnology company developing a “potent” oral small molecule, IMU-838, for multiple sclerosis, the analyst tells investors in a research note. The firm believes IMU-838 can potentially introduce a new treatment paradigm in the multiple sclerosis space.